Full-Time

Manager – Csv

Posted on 8/27/2025

Cellectis

Cellectis

201-500 employees

Develops allogeneic CAR-T cell therapies

No salary listed

Raleigh, NC, USA

In Person

Category
Biology & Biotech (2)
,
Required Skills
Oracle
Requirements
  • Bachelor’s degree in a technical/science/mathematical field, required.
  • Minimum 5-8 years validation experience in a biotech/pharmaceutical environment.
  • Minimum 1 year experience managing validation functional area.
  • Experience with SAAS, IAAS, and PAAS software implementations.
  • Enterprise Systems: Experience with using Off-the-shelf, Configured-Off-The-Shelf (COTs), and Bespoke Computerized Systems such as CRM, LMS, ERP (Oracle), LIMS, ELN, etc.
  • Test Script Development: Experience writing and executing functional and performance test scripts.
  • Previous leadership experiences required.
Responsibilities
  • Develop and manage CSV lifecycle documentation: Validation Plans, User Requirements Specifications (URS), Functional Specifications (FS), Design Specifications (DS), IQ/OQ/PQ protocols, and Summary Reports.
  • Ensure validation activities meet FDA, EMA, and other global regulatory standards.
  • Identify and support the resolution of deviations noted during protocol execution; Take part in the resolution of departmental related deviations.
  • Lead validation efforts for systems such as eQMS, EMS, ERP (Oracle), and other GMP-critical platforms.
  • Responsible for authoring, revising, and maintaining Validation Master Plans of Global Computerized Systems.
  • Validate integration points between automation systems and enterprise platforms (e.g., MES to ERP, MES to LIMS).
  • Conduct risk assessments to determine appropriate validation rigor based on system impact and complexity.
  • Implement CSA principles to streamline validation of low-risk systems while maintaining compliance.
  • Promote CSA methodologies to reduce documentation burden and enhance testing efficiency to ensure robust, efficient, and compliant processes.
  • Ensure systems comply with 21 CFR Part 11, EU Annex 11, GAMP 5, and internal SOPs.
  • Follow departmental and Global/company-wide SOPs and policies, including Global Computerized System VMP and Policies.
  • Lead investigations and CAPAs related to system failures or deviations.
  • Present findings and results from completed validation deliverables in customer and internal audits, Support regulatory audits, as necessary.
  • Requalification and periodic review schedule adherence for computerized systems and IT processes per procedure and established plans; Analyzes and summarizes periodic reviews of previously validated computerized systems and develop/implement protocols/changes based on outcome of the review.
  • Support internal audits and regulatory inspections by providing validation documentation and system evidence.
  • Attend internal meetings to support computerized system validation topics.
  • Coordinate validation schedules, resource allocation, and project timelines.
  • Fosters a positive work environment.
  • Manage cross-functional teams including QA, IT, automation engineers, and business users.
  • Participates with CSV team to establish the annual goals and desired culture.
  • Train and mentor staff on CSV, CSA, and automation compliance best practices.
  • Serve as the subject matter expert to provide compliance and oversight to cross-functional team's CSV and/or CSA projects.
  • Ensure traceability from requirements through testing and release.
  • Maintain accurate and complete documentation for all validated systems.
  • Review and approve change control requests impacting validated systems.
  • Lead initiatives to enhance validation efficiency and system reliability.
  • Monitor system performance and validation metrics to identify improvement opportunities.
  • Stay current with evolving regulatory expectations and industry best practices.
  • Travel up to 10% of the time.

Cellectis develops immunotherapy treatments for cancer using gene-edited allogeneic CAR T cells. Its products rely on donor-derived T cells that are edited to remove T cell receptor activity and engineered to express a chimeric antigen receptor (CAR) that targets cancer cells. The goal is to create off-the-shelf CAR T therapies that are available quickly and at a lower cost than patient-specific (autologous) CAR T treatments. Cellectis works through research and development, clinical trials, and partnerships with other pharma companies, such as Sanofi, and generates revenue from licensing, milestone payments, and potential future product sales. The company differentiates itself by offering off-the-shelf solutions rather than custom-made therapies, aiming to broaden access to advanced cancer treatment.

Company Size

201-500

Company Stage

IPO

Headquarters

Paris, France

Founded

2000

Simplify Jobs

Simplify's Take

What believers are saying

  • Positive pivotal data for Allogene’s cema-cel validates Cellectis’ TALEN-edited allogeneic CAR T platform and de-risks the technology.
  • Encouraging early eti-cel and lasme-cel results support potential registration paths in NHL and B-ALL by 2028.
  • Cellectis’ $188 million cash runway into Q4 2027 funds pivotal trials and platform expansion without immediate dilution.

What critics are saying

  • Small eti-cel cohorts and unproven IL-2 combinations risk disappointing full Phase 1 data and delayed timelines.
  • Allogene’s lead in UCART19 commercialization captures most of the value from Cellectis’ licensed assets.
  • Analyst downgrades and compressed 2026 revenue forecasts increase pressure to raise capital at potentially dilutive valuations.

What makes Cellectis unique

  • Cellectis pioneered allogeneic, off-the-shelf CAR T cells using its proprietary TALEN gene-editing platform.
  • The company controls the full cell and gene therapy value chain from discovery through GMP manufacturing.
  • Cellectis’ UCART programs integrate suicide switches and multi-targeting CAR designs to enhance safety and efficacy.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Mar 19th, 2026
Cellectis Q4 2025 earnings preview: Revenue expected at $14.90M, analysts forecast -$0.24 per share

Cellectis SA is set to release its Q4 2025 earnings on 20 March 2026. Analysts expect revenue of $14.90 million and losses of $0.24 per share for the quarter. Full-year 2025 revenue is forecast at $58.42 million with losses of $0.73 per share. Over the past 90 days, revenue estimates for 2025 have increased from $55.17 million to $58.42 million, whilst earnings estimates improved from losses of $0.87 per share to $0.73 per share. However, 2026 revenue estimates have declined from $69.51 million to $53.66 million. In Q3 2025, Cellectis exceeded expectations with revenue of $32.37 million against estimates of $6.01 million. The average analyst price target suggests 113% upside from the current price of $3.08.

GlobeNewswire
Mar 12th, 2026
Cellectis will publish its financial results for the fourth quarter and full year 2025 on March 19, 2026.

Cellectis will publish its financial results for the fourth quarter and full year 2025 on March 19, 2026. March 12, 2026 16:30 ET | Source: Cellectis Inc. NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) - Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company that uses its pioneering TALEN(R) genome editing technology to develop innovative therapies for the treatment of serious diseases, will publish its financial results for the fourth quarter and fiscal year 2025 ended December 31, 2025, on Thursday, March 19, 2026 after the U.S. market close. A conference call will be held on Friday, March 20, 2026 at 1:00 PM Paris time - 8:00 AM New York time. The conference will cover the Company's results for the fourth quarter and year 2025 as well as a business update. Telephone numbers and link to listen to the live conference: Live (US / Canada): 1-800-579-2543 Live (International): 1-785-424-1789 Conference ID: CLLSFY Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1747993&tp_key=8aa72cea7f About Cellectis Cellectis is a clinical-stage biotechnology company that uses its pioneering genome editing platform to develop innovative cell and gene therapies for the treatment of serious diseases. Cellectis is developing the first allogeneic CAR-T immunotherapy products, inventing the concept of off-the-shelf engineered CAR T cells for the treatment of cancer patients, and a platform for developing gene therapies in other therapeutic indications. With its fully internalized manufacturing capabilities, Cellectis is one of the few companies in genome editing to control the entire value chain of cell and gene therapy from end to end. Cellectis' headquarters are located in Paris. Cellectis also has offices in New York and Raleigh in the United States. Cellectis is listed on the Euronext Growth market (code: ALCLS) as well as on the Nasdaq Global Market (code: CLLS). To learn more, visit our website: www.cellectis.com and follow Cellectis on LinkedIn and X. For further information about Cellectis, please contact: Media Contacts: Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, [email protected] Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93 Investor Relations Contact: Arthur Stril, Chief Financial Officer & Chief Business Officer, [email protected] Attachment

Stock Titan
Nov 3rd, 2025
Cellectis to Present a Development Update for eti-cel at ASH 2025

Cellectis to present a development update for eti-cel at ASH 2025. Cellectis (NASDAQ: CLLS) announced two accepted posters for ASH 2025 (Dec 6 - 9, 2025) in Orlando reporting clinical updates on allogeneic CAR-T programs eti-cel (UCART20x22) and lasme-cel (UCART22). Preliminary eti-cel Phase 1 results show an 86% ORR and 57% CR at the current dose (n=7); Cellectis plans to present the full Phase 1 dataset, including low-dose IL-2 combination cohorts, in 2026. A preclinical signal suggests low-dose IL-2 may deepen and extend anti-tumor activity. The lasme-cel poster reports a correlation between alemtuzumab exposure and depth of response in BALLI-01, identifying a threshold exposure linked to higher CR/CRi rates without increased toxicities and supporting planned pivotal Phase 2 enrollment in Q4 2025. * Eti-cel preliminary 86% ORR (n=7) * Eti-cel preliminary 57% CR (4 of 7 patients) * Full eti-cel Phase 1 dataset including IL-2 cohorts expected in 2026 * Alemtuzumab exposure threshold linked to higher CR/CRi without added toxicity * Eti-cel preliminary results are from a small cohort of n=7 * Full clinical impact of IL-2 combination not yet shown pending 2026 dataset 11/03/2025 - 09:15 AM * Preliminary data recently shared for eti-cel (UCART20x22) show an 86% ORR and a 57% CR rate (n=7), underscoring its potential to improve outcomes in r/r NHL * Preclinical data demonstrated that combining eti-cel with low-dose IL-2 may deepen and extend anti-tumor activity in patients with r/r NHL * Eti-cel full Phase 1 dataset, including low-dose IL-2 combination cohorts, expected to be presented in 2026 * Correlation between alemtuzumab exposure and response with lasme-cel (UCART22) allows optimization of efficacy without an increase in toxicities NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) - Cellectis (the "Company") (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the acceptance of two abstracts for poster presentation at the American Society of Hematology (ASH) 2025 annual meeting taking place from December 6 to 9, 2025, in Orlando, FL. First poster - Development update on eti-cel The first poster provides a development update on eti-cel product candidate (UCART20x22), an allogeneic dual CAR-T targeting CD20 and CD22 being developed in Phase 1 of the NATHALI-01 clinical trial, for patients with relapsed/refractory non Hodgkin lymphoma (r/r NHL). In addition, the poster outlines the addition of low dose interleukin-2 (IL-2) to further deepen and extend anti-tumor activity of eti-cel in patients with r/r NHL, supported by compelling preclinical data. Cellectis unveiled preliminary results on eti-cel, which demonstrate an encouraging overall response rate (ORR) of 86% and a complete response (CR) rate of 57% at the current dose level (n=7), with 4 out of 7 patients achieving a complete response. The preliminary high rate of complete responses underscores the potential of this innovative approach to transform outcomes for r/r NHL patients. Cellectis expects to present the full Phase 1 dataset for eti-cel, including low-dose IL-2 combination cohorts, in 2026. "We are excited by the progress and evolution of the eti-cel program with the addition of IL-2, which promises to build on the encouraging preliminary response rates observed in the Phase 1 program," said Adrian Kilcoyne, MD, MPH, MBA, Chief Medical Officer at Cellectis. "We look forward to sharing the full Phase 1 dataset including the IL-2 cohorts expected in 2026." Presenter: Vivian Dai, Senior Director, Clinical Research Scientist at Cellectis Date/Time: December 7, 2025 at 6:00 PM - 8:00 PM ET The second poster highlights the correlation between alemtuzumab exposure and depth of response in the difficult-to-treat patients who have received lasme-cel (UCART22) in the course of the Phase 1 of BALLI-01, a clinical trial testing this allogeneic CAR-T product candidate targeting CD22 in relapsed/refractory acute lymphoblastic leukemia (ALL). Additionally, the data identifies a threshold exposure level of alemtuzumab above which achieving a complete response/complete response with incomplete hematologic recovery (CR/CRi) is more likely without any increase in toxicities. "We strongly believe in the critical role of alemtuzumab in optimizing responses in these heavily pretreated patients," said Adrian Kilcoyne, MD, MPH, MBA, Chief Medical Officer at Cellectis. "These data have confirmed this and demonstrated that we could further enhance the high CR/CRi and minimal residual disease (MRD)-negative rates observed in our Phase 1 program. We look forward to starting enrollment in our pivotal Phase 2 program in Q4 2025." Presenter: Xenia Naj, Ph.D., Director Translational Sciences at Cellectis Date/Time: December 8, 2025, 6:00 PM - 8:00 PM These abstracts can now be accessed here About Cellectis Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Cellectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish. Cellectis' headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more, visit www.cellectis.com and follow Cellectis on LinkedIn and X. This press release contains "forward-looking" statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as "designed to," "believe," "could," "expect," "expected," "look forward," "may," "promise," or the negative of these and similar expressions. These forward-looking statements, which are based on our management's current expectations and assumptions and on information currently available to management, include statements regarding the potential of the Phase 2 BALLI-01 trial to be a registrational phase, the advancement, timing and progress of clinical trials (including with respect to patient enrollment and follow-up), the timing of our presentation of data and submission of regulatory filings, the sufficiency of cash to fund operations, the potential benefit of our product candidates and technologies. These forward-looking statements are made in light of information currently available to us and are subject to significant risks and uncertainties, including with respect to the numerous risks associated with biopharmaceutical product candidate development. Furthermore, many other important factors, including those described in our Annual Report on Form 20-F as amended and in our annual financial report (including the management report) for the year ended December 31, 2024 and subsequent filings Cellectis makes with the Securities Exchange Commission from time to time, which are available on the SEC's website at www.sec.gov, as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. For further information on Cellectis, please contact: Media contacts: Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, [email protected] Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93 Investor Relations contact: Arthur Stril, Chief Financial Officer & Chief Business Officer, [email protected] What eti-cel (UCART20x22) results will Cellectis (CLLS) present at ASH 2025? Cellectis will present a development update; preliminary Phase 1 data show an 86% ORR and 57% CR at the current dose (n=7), with full Phase 1 data expected in 2026. When and where will the eti-cel poster (CLLS) be presented at ASH 2025? The eti-cel poster is scheduled for December 7, 2025, 6:00 - 8:00 PM ET in Room OCCC West Halls B3-B4. What does the lasme-cel (UCART22) poster for Cellectis (CLLS) report about alemtuzumab? The poster shows a correlation between alemtuzumab exposure and deeper responses, identifying a threshold associated with higher CR/CRi rates without increased toxicities. How does the alemtuzumab finding affect Cellectis' clinical plans (CLLS)? Cellectis cites the exposure - response data as supporting the start of pivotal Phase 2 enrollment in Q4 2025. Will Cellectis (CLLS) present full eti-cel IL-2 combination data at ASH 2025? No; Cellectis expects to present the full Phase 1 dataset including low-dose IL-2 cohorts in 2026.

PR Newswire
Sep 26th, 2025
Factor Bioscience Files Complaint Against Cellectis and AstraZeneca Alleging Infringement of Foundational Gene-Editing Patents

Factor Bioscience files complaint against Cellectis and AstraZeneca alleging infringement of foundational gene-editing patents.

GlobeNewswire
Aug 7th, 2025
Monthly information on share capital and company voting rights

Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies.

INACTIVE